Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer. Goto K, Ando K, Motoi N, Iizuka T, et al. Anticancer Res 2026;46:2445-2453.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Goto K, Ando K, Motoi N, Iizuka T, et al. Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer. Anticancer Res 2026;46:2445-2453.
PMID: 42049372